MG-262 (Z-Leu-Leu-Leu-B(OH)2): A Reversible, Cell-Permeable Proteasome Inhibitor

Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a boronic acid-based, reversible proteasome inhibitor with an IC₅₀ of 122 nM for proteasome chymotryptic activity in vitro, offering high selectivity and cell permeability (APExBIO, product page). The compound is soluble to ≥24.57 mg/mL in DMSO and ≥96.4 mg/mL in ethanol, but insoluble in water. MG-262 induces cell growth arrest, DNA replication inhibition, and apoptosis via mitochondrial and caspase-3 pathways (Kim 2012, DOI). It is widely used to model ubiquitin-proteasome system functions and is a benchmark reference for studies in cancer, inflammation, and neurodegeneration (Nature Metabolism 2025). Correct storage at -20°C and immediate use after solution preparation are essential due to solution instability.

Biological Rationale

The ubiquitin-proteasome system (UPS) is the dominant pathway for regulated protein degradation in eukaryotic cells. UPS controls cell cycle progression, apoptosis, and stress responses by targeting specific proteins for degradation. Dysregulation of UPS activity is implicated in cancer, inflammatory diseases, neurodegenerative disorders, and muscle wasting syndromes (Nature Metabolism 2025, DOI). Proteasome inhibitors like MG-262 are powerful research tools for probing these pathologies by reversibly blocking proteasome function and enabling mechanistic studies of protein homeostasis. Chaperone-mediated autophagy (CMA) and macroautophagy coexist with UPS, and their interplay is crucial for muscle function and adaptation (Nature Metabolism 2025). MG-262’s specificity makes it suitable for dissecting proteasome roles distinct from lysosomal degradation pathways.

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a boronic peptide acid composed of a Z-Leu-Leu-Leu peptide backbone covalently linked to a boronic acid moiety. The boronic acid forms a reversible covalent bond with the catalytic threonine of the proteasome’s chymotrypsin-like active site. This interaction selectively and reversibly blocks proteasome-mediated peptide bond hydrolysis. The compound exhibits an IC₅₀ of 122 nM (chymotryptic activity, cell-free assay, 37°C, pH 7.4; APExBIO). MG-262 is cell-permeable, enabling intracellular proteasome inhibition without requiring membrane permeabilization. The reversible nature of its inhibition allows for dose-dependent and time-resolved studies of proteasome activity.

Evidence & Benchmarks

• MG-262 inhibits proteasome chymotryptic activity with an IC₅₀ of 122 nM under physiological conditions (APExBIO).
• Solubility is confirmed at ≥24.57 mg/mL in DMSO and ≥96.4 mg/mL in ethanol, but the compound is insoluble in water (APExBIO, product page).
• MG-262 induces cell growth arrest and inhibits DNA replication in nasal mucosa and polyp fibroblasts (Kim 2012, DOI).
• Apoptosis induction is mediated by mitochondrial membrane potential loss, caspase-3 activation, and PARP cleavage (Kim 2012, DOI).
• MG-262 effectively inhibits osteoclast differentiation in vitro in a dose-dependent manner (APExBIO, product page).
• In vivo, systemic administration reduces proteasome activity in multiple organs, supporting its use for whole-animal studies (APExBIO, product page).
• Proteasome inhibition by MG-262 provides a functional benchmark for studies of muscle proteostasis and atrophy, as in the referenced Nature Metabolism study (DOI).

For a protocol-driven guide and troubleshooting strategies, see MG-262: Reversible Proteasome Inhibition for Advanced Cell Studies. This article extends prior work by integrating new findings on CMA and muscle aging mechanisms.

For comparison with other cell-permeable proteasome inhibitors and application-specific benchmarks, see MG-262: Advanced Reversible Proteasome Inhibitor for Precision Research. The present review updates selectivity data and integrates recent in vivo insights.

For a translational perspective on proteostasis research and MG-262’s role, see Translational Acceleration in Proteostasis Research. Here, we clarify experimental boundaries and new applications in muscle aging models.

Applications, Limits & Misconceptions

MG-262 is widely employed in cancer, inflammatory disease, and neurodegenerative models to elucidate the roles of the ubiquitin-proteasome system in cell cycle control, apoptosis, and protein homeostasis. It is particularly valuable for:

• Cell cycle arrest studies via monitoring p21 and p27 upregulation.
• Apoptosis research through caspase-3 activation and mitochondrial membrane dynamics.
• Osteoclast differentiation inhibition in vitro, relevant for bone homeostasis studies.
• Modeling proteasome dysfunction in muscle atrophy and neurodegeneration (Nature Metabolism 2025, DOI).
• Validation and benchmarking of proteasome inhibition assays across disease models.

MG-262 is not suitable for lysosome-specific degradation studies or for distinguishing between macroautophagy and chaperone-mediated autophagy, as it acts upstream in the protein degradation hierarchy (Nature Metabolism 2025). It is recommended to use freshly prepared solutions due to instability in aqueous buffers and to store powder at -20°C (APExBIO).

Common Pitfalls or Misconceptions

• MG-262 does not inhibit lysosomal proteases or autophagy directly; its primary target is the proteasome.
• It is ineffective in water-based solutions due to insolubility; only DMSO or ethanol should be used as solvents.
• MG-262’s effects are reversible; prolonged exposure or repeated dosing may be necessary for sustained inhibition.
• Proteasome inhibition can trigger compensatory activation of autophagic pathways, which may confound interpretation if not controlled (Nature Metabolism 2025).
• Not all cell types respond identically; dosing and kinetics must be empirically optimized for each model system.

Workflow Integration & Parameters

For optimal results, MG-262 (A8179, APExBIO) should be dissolved in DMSO to ≥24.57 mg/mL or in ethanol to ≥96.4 mg/mL. Solutions should be freshly prepared immediately prior to use to prevent hydrolysis or degradation. For in vitro applications, recommended concentrations typically range from 50 nM to 1 μM, with exposure times from 30 minutes to 24 hours, depending on the desired endpoint. For in vivo studies, intravenous administration delivers systemic proteasome inhibition, but pharmacokinetics and tissue penetration should be characterized for each protocol.

MG-262 is compatible with proteasome activity assays, apoptosis detection (Annexin V, caspase-3, PARP cleavage), cell cycle analysis (flow cytometry, p21/p27 staining), and osteoclastogenesis assays. Careful solvent controls and parallel viability measurements are recommended. For long-term storage, keep the powder at -20°C in a desiccated environment.

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a validated, reversible, and cell-permeable proteasome inhibitor with broad utility in mechanistic and translational research. Its defined selectivity, solubility, and inhibitory profile enable precise modeling of UPS dysfunction in cancer, inflammation, neurodegeneration, and muscle aging. As new roles for proteasome and autophagy pathways emerge—such as CMA’s contribution to muscle integrity—MG-262 remains a gold-standard tool for dissecting protein homeostasis. For detailed specifications, protocols, and ordering, refer to the APExBIO MG-262 product page.